Incannex Healthcare (NASDAQ:IXHL) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Incannex Healthcare (NASDAQ:IXHL – Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other research analysts also recently commented on the company. Zacks Research downgraded Incannex Healthcare from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Incannex Healthcare in a report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Incannex Healthcare currently has a consensus rating of “Reduce” and a consensus price target of $18.00.

Check Out Our Latest Stock Analysis on Incannex Healthcare

Incannex Healthcare Stock Performance

Shares of IXHL stock opened at $1.86 on Friday. The firm’s 50 day moving average price is $2.78 and its two-hundred day moving average price is $3.66. The stock has a market cap of $23.34 million, a PE ratio of -1.50 and a beta of 7.00. Incannex Healthcare has a 52-week low of $1.61 and a 52-week high of $14.91.

Incannex Healthcare (NASDAQ:IXHL – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.29. As a group, sell-side analysts predict that Incannex Healthcare will post -2.63 earnings per share for the current fiscal year.

Incannex Healthcare Company Profile

(Get Free Report)

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing investigational medicines, including cannabinoid-based combination therapies and psychedelic-assisted treatments. Its research focuses on conditions with significant unmet medical needs; its products are in development and are not established as approved treatments. The company’s pipeline has included IHL-42X, a combination of dronabinol and acetazolamide being studied for obstructive sleep apnea, as well as programs targeting inflammatory conditions and traumatic brain injury.

Further Reading

Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.